S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Buy THIS stock before Taiwan is attacked (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Buy THIS stock before Taiwan is attacked (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Buy THIS stock before Taiwan is attacked (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Buy THIS stock before Taiwan is attacked (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
BREAKING: Tiny biotech successfully treats blindness (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
BREAKING: Tiny biotech successfully treats blindness (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:VCEL

Vericel - VCEL Price Target & Analyst Ratings

$28.97
+0.16 (+0.56%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$28.04
$29.02
50-Day Range
$27.03
$31.34
52-Week Range
$17.30
$41.24
Volume
193,423 shs
Average Volume
427,282 shs
Market Capitalization
$1.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50

Vericel Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$35.50
22.54% Upside
High Prediction$40.00
Average Prediction$35.50
Low Prediction$31.00
TypeCurrent
3/26/22 to 3/26/23
1 Month Ago
2/24/22 to 2/24/23
3 Months Ago
12/26/21 to 12/26/22
1 Year Ago
3/26/21 to 3/26/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$35.50$37.00$35.80$54.00
Predicted Upside22.54% Upside25.40% Upside35.05% Upside21.10% Upside
Get Vericel Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

VCEL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VCEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vericel Stock vs. The Competition

TypeVericelMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside22.54% Upside2,007.53% Upside23.66% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/27/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold$29.00 ➝ $31.00+1.01%
1/27/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$37.00+32.85%
11/9/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
10/13/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$40.00+60.97%
2/25/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$40.00 ➝ $45.00+15.74%
6/30/2021Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
1/19/2021LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$27.50 ➝ $44.00+12.76%
8/5/2020Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chad Messer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
(Data available from 3/26/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












VCEL Price Target - Frequently Asked Questions

What is Vericel's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Vericel stock is Moderate Buy based on the current 2 hold ratings and 2 buy ratings for VCEL. The average twelve-month price prediction for Vericel is $35.50 with a high price target of $40.00 and a low price target of $31.00. Learn more on VCEL's analyst rating history.

Do Wall Street analysts like Vericel more than its competitors?

Analysts like Vericel less than other Medical companies. The consensus rating for Vericel is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how VCEL compares to other companies.

Does Vericel's stock price have much upside?

According to analysts, Vericel's stock has a predicted upside of 27.88% based on their 12-month price targets.

What analysts cover Vericel?

Vericel has been rated by HC Wainwright, and Truist Financial in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:VCEL) was last updated on 3/26/2023 by MarketBeat.com Staff